Human Presenilin 1 quantitates human Presenilin 1 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human Presenilin 1.
Human Presenilin 1 quantitates human Presenilin 1 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human Presenilin 1.
Human Presenilin 1 quantitates human Presenilin 1 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human Presenilin 1.
Presenin1 was first identified as a marker of susceptibility to early onset Alzheimer's disease. In addition to PEN2, nicastrin, and APH-1, presenilin1 forms the gamma-secretase protein complex, a membrane-bound aspartyl protease that can clivate certain proteins to peptide bonds buried in the hydrophobic environment of the lipid bilayer. This cleavage is responsible for a key step in signalling from several cell surface receptors and is considered necessary for the generation of neurotoxic amyloid peptides that are essential to the pathogenesis of Alzheimer's disease. Like the alpha tumour necrosis factor (TACE) conversion enzyme and beta cleavage enzyme (BACE) protease families, gamma secretase clives the amyloid precursor protein (APP), but within the intramembrane region of the APP, which produces nontoxic p3 (from the alpha and gamma cleavage site), the toxic Abeta amyloid peptide (from the beta and gamma cleavage site). It is believed that the accumulation of the Abeta peptide is the precursor of Alzheimer's disease. There are several isoforms of presenin1.
Sensitivity
Sensitivity of the dosage: 10.5 pg/ml.
Measurement range
Dose range: 10.5 to 2.500 pg/ml.
Duration of dosing
Total duration of dosing: 4 h 45 min.
Target
Target: Presenilin 1.
Samples
Type of sample: Plasma, Serum, Surnatant (surnatant volume, 50 µl; serum, 50 µl; plasma, 50 µl).